Zhu Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhu Liang has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Roman Fischer
Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
11 shared publications - Adrian L. Harris
Department of Oncology, University of Oxford, Oxford, UK
10 shared publications - Aik Seng Ng
Nuffield Department of Clinical Laboratory Sciences, Radcliffe Department of Medicine University of Oxford Oxford UK
10 shared publications - Balázs Győrffy
Semmelweis University
10 shared publications - David J. Kerr
Nuffield Divisio Medical Labaratory Science, Radcliffe Department of Medicine John Radcliffe Hospital, Oxford OX3 9DU, UK
10 shared publications - Esther Bridges
MRC Translational Immune Discovery Unit, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford , Oxford
10 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (7) , 1949-1966
IL-22 promotes genesis of small intestinal secretory cells that protect against cholera in mice
The diarrhoeal disease cholera remains a global threat, but there is limited knowledge of the innate immune defences in the small intestine that protect against the causative agent, Vibrio cholerae. Here single-cell RNA sequencing of epithelial and immune cells mapped gene expression patterns in the infant mouse small intestine and revealed changes in response to V. cholerae infection and prophylactic treatment with an interleukin-22-immunoglobulin Fc region (IL-22Fc)-fusion protein. Infection increased the abundance of an enterocyte subtype with high expression of defence-associated functions and stimulated production of IL-22, a cytokine linked to epithelial integrity, from group 3 innate lymphoid cells. Administration of IL-22Fc increased production of vibriocidal Reg3β from enterocytes and the abundance of secretory lineage and Muc2-producing goblet cells, which secreted mucus into the intestinal crypts, impairing V. cholerae association with the epithelium. These IL-22-mediated responses limited V. cholerae intestinal colonization and protected mice from diarrhoea and death. Our findings suggest enterocyte specialization in mucosal defence.
- 3 June 2026
- Published by Springer Nature in Nature Microbiology
- Vol. 11 (7) , 1949-1966
Open AccessIL-22 promotes genesis of small intestinal secretory cells that protect against cholera in mice
The diarrhoeal disease cholera remains a global threat, but there is limited knowledge of the innate immune defences in the small intestine that protect against the causative agent, Vibrio cholerae. Here single-cell RNA sequencing of epithelial and immune cells mapped gene expression patterns in the infant mouse small intestine and revealed changes in response to V. cholerae infection and prophylactic treatment with an interleukin-22-immunoglobulin Fc region (IL-22Fc)-fusion protein. Infection increased the abundance of an enterocyte subtype with high expression of defence-associated functions and stimulated production of IL-22, a cytokine linked to epithelial integrity, from group 3 innate lymphoid cells. Administration of IL-22Fc increased production of vibriocidal Reg3β from enterocytes and the abundance of secretory lineage and Muc2-producing goblet cells, which secreted mucus into the intestinal crypts, impairing V. cholerae association with the epithelium. These IL-22-mediated responses limited V. cholerae intestinal colonization and protected mice from diarrhoea and death. Our findings suggest enterocyte specialization in mucosal defence.
- Open Access
- 16 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Amino acid and viral binding by the high-affinity Cationic Amino acid Transporter 1 (CAT1) from Mus musculus
Arginine, lysine, and ornithine are critical to several fundamental aspects of organismal physiology, including protein structure and function, the urea cycle, and intracellular signaling. These cationic amino acids are imported by several membrane transporters, most notably the Cationic Amino acid Transporters (CATs) in the SLC7 family. Of these, CAT1 is also the receptor for two orthoretroviruses, and determines the host tropism for these viruses. Here, using a combination of CryoEM and in vitro biochemical techniques, we characterize the substrate recognition and transport of CAT1 from Mus musculus . Further, by determining the structures of MmCAT1 in complex with the receptor binding domain from the Friend Murine Leukemia Virus, we identify the key structural interactions that determine the virus’ rodent-specific tropism.
- 16 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAmino acid and viral binding by the high-affinity Cationic Amino acid Transporter 1 (CAT1) from Mus musculus
Arginine, lysine, and ornithine are critical to several fundamental aspects of organismal physiology, including protein structure and function, the urea cycle, and intracellular signaling. These cationic amino acids are imported by several membrane transporters, most notably the Cationic Amino acid Transporters (CATs) in the SLC7 family. Of these, CAT1 is also the receptor for two orthoretroviruses, and determines the host tropism for these viruses. Here, using a combination of CryoEM and in vitro biochemical techniques, we characterize the substrate recognition and transport of CAT1 from Mus musculus . Further, by determining the structures of MmCAT1 in complex with the receptor binding domain from the Friend Murine Leukemia Virus, we identify the key structural interactions that determine the virus’ rodent-specific tropism.
- Open Access
- 25 October 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (4) , 103417
Protocol to profile spatially resolved NLRP3 inflammasome complexes using APEX2-based proximity labeling
- 25 October 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (4) , 103417
Open AccessProtocol to profile spatially resolved NLRP3 inflammasome complexes using APEX2-based proximity labeling
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
Supplementary Figures from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
GTP cyclohydrolase (GCH1) is the rate-limiting enzyme for tetrahydrobiopterin (BH4) biosynthesis. The catalysis of BH4 biosynthesis is tightly regulated for physiological neurotransmission, inflammation, and vascular tone. Paradoxically, BH4 has emerged as an oncometabolite regulating tumor growth, but the effects on tumor development remain controversial. Here we found that GCH1 potentiates the growth of triple-negative breast cancer (TNBC) and HER2+ breast cancer and transforms non-tumor breast epithelial cells. Independent of BH4 production, GCH1 protein induced epithelial-to-mesenchymal transition IEMT) by binding to Vim, which was mediated by HSP90. Conversely, GCH1 ablation impaired tumor growth, suppressed Vim in TNBC, and inhibited EGFR/ERK signaling while activating the p53 pathway in estrogen receptor-positive tumor cells. GCH1 deficiency increases tumor cell sensitivity to HSP90 inhibition and endocrine treatments. Additionally, high GCH1 corelated with poor breast cancer survival. Together, this study reveals an enzyme-independent oncogenic role of GCH1, presenting it as a potential target for therapeutic development.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner
GTP cyclohydrolase (GCH1) is the rate-limiting enzyme for tetrahydrobiopterin (BH4) biosynthesis. The catalysis of BH4 biosynthesis is tightly regulated for physiological neurotransmission, inflammation, and vascular tone. Paradoxically, BH4 has emerged as an oncometabolite regulating tumor growth, but the effects on tumor development remain controversial. Here we found that GCH1 potentiates the growth of triple-negative breast cancer (TNBC) and HER2+ breast cancer and transforms non-tumor breast epithelial cells. Independent of BH4 production, GCH1 protein induced epithelial-to-mesenchymal transition IEMT) by binding to Vim, which was mediated by HSP90. Conversely, GCH1 ablation impaired tumor growth, suppressed Vim in TNBC, and inhibited EGFR/ERK signaling while activating the p53 pathway in estrogen receptor-positive tumor cells. GCH1 deficiency increases tumor cell sensitivity to HSP90 inhibition and endocrine treatments. Additionally, high GCH1 corelated with poor breast cancer survival. Together, this study reveals an enzyme-independent oncogenic role of GCH1, presenting it as a potential target for therapeutic development.